Read by QxMD icon Read

Annals of Hematology

Andry Van de Louw, Allyson M Lewis, Zhaohai Yang
We aimed to report autopsy findings in patients with acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL) in the modern era, and also to focus on lung pathology in the subgroup of patients with acute respiratory failure (ARF) of unknown etiology, which is associated with especially high mortality rates. Charts and autopsy reports of 107 patients (59 AML and 48 NHL) autopsied between 2003 and 2018 were reviewed. More than 50% of patients had missed major diagnoses found at autopsy with 95% of lungs displaying abnormal findings...
September 14, 2018: Annals of Hematology
Guillaume Dumas, Lucie Biard, Claire Givel, Sandy Amorim, Lara Zafrani, Virginie Lemiale, Eric Mariotte, Elie Azoulay, Catherine Thiéblemont, Emmanuel Canet
T cell non-Hodgkin lymphomas (T-NHLs) are aggressive malignancies which have a high risk of life-threatening complications. However, their prognosis in the intensive care unit (ICU) setting has not yet been assessed. We conducted a study including 87 ICU patients either with newly diagnosed T-NHLs or those undergoing first-line therapy admitted between January 1, 2000, and December 31, 2014. The primary subtypes were peripheral T cell lymphoma (PTCL) (n = 41, 47%), anaplastic large-cell lymphoma (ALCL) (n = 13, 15%), and adult T-leukaemia/lymphoma (ATLL) (n = 11, 13%)...
September 14, 2018: Annals of Hematology
Yan Zhang, Wei Zhang, Jian Li, Minghui Duan, Bing Han, Tienan Zhu, Junling Zhuang, Huacong Cai, Xinxin Cao, Miao Chen, Daobin Zhou
Peripheral T cell lymphomas (PTCL) are less responsive to anthracycline-containing regimen such as CHOP and carry a poor prognosis. In this prospective study, we investigated gemcitabine, cisplatin, and dexamethasone (GDP) combined with methotrexate (MTX) and pegaspargase (PEG-L) as front-line treatment in PTCL. Eligible newly diagnosed PTCL patients received 4 cycles of the GDP-ML chemotherapy every 28 days. After 4 cycles, responding patients continued to receive either autologous stem cell transplantation or the MTX/cytarabine (MA) regimen for consolidation...
September 12, 2018: Annals of Hematology
Helena Claerhout, Els Lierman, Lucienne Michaux, Gregor Verhoef, Nancy Boeckx
As diagnosing therapy-related myeloid neoplasms (t-MN) is often challenging, we reviewed clinicopathological features of t-MN patients. Medical records of 138 patients, diagnosed with t-MN between 1995 and 2017, were reviewed. Of 138 patients, 80 had t-MDS, 53 t-AML, and 5 t-MDS/MPN (age, 22-88 years; median 64 years; male/female ratio, 0.8). The median latency time was 6 years and 5 months. Of 115 patients, 56 patients received cytotoxic-/radiotherapy for a solid tumor, 56 for hematological malignancy, and 3 for an auto-immune disorder, respectively...
September 10, 2018: Annals of Hematology
Ersi Voskaridou, Antonis Kattamis, Christina Fragodimitri, Alexandra Kourakli, Panagiota Chalkia, Michael Diamantidis, Efthymia Vlachaki, Marouso Drosou, Stilianos Lafioniatis, Konstantinos Maragkos, Fotini Petropoulou, Eftihios Eftihiadis, Marina Economou, Evangelos Klironomos, Freideriki Koutsouka, Konstantina Nestora, Ioanna Tzoumari, Ourania Papageorgiou, Artemis Basileiadi, Ioannis Lafiatis, Efthimia Dimitriadou, Anastasia Kalpaka, Chrysoula Kalkana, Georgios Xanthopoulidis, Ioannis Adamopoulos, Panagiotis Kaiafas, Aikaterini Mpitzioni, Anastasia Goula, Ioannis Kontonis, Chrisoula Alepi, Athanasios Anastasiadis, Margarita Papadopoulou, Polixeni Maili, Dionisia Dionisopoulou, Antigoni Tsirka, Alexandros Makis, Stavroula Kostaridou, Marianna Politou, Ioannis Papassotiriou
National registries constitute an invaluable source of information and contribute to the improvement of hemoglobinopathy management. Herein, we present the second updated report of the National Registry for Haemoglobinopathies in Greece (NRHG) and critically discuss the time trends in demographics, affected births, and causes of mortality. Thirty-eight Greek hemoglobinopathy units reported data from diagnosis to the last follow-up or death by retrospectively completing an electronic form. Four thousand thirty-two patients were eligible for inclusion; more than half of them had thalassaemia major...
September 8, 2018: Annals of Hematology
Hammad Tashkandi, Mark L Cohen, Marta E Couce
No abstract text is available yet for this article.
September 4, 2018: Annals of Hematology
Mette Vestergaard Elbæk, Anders Lindholm Sørensen, Hans Carl Hasselbalch
Patients with chronic myelomonocytic leukemia (CMML) have monocytosis and likely a state of chronic inflammation. Both have been associated with an increased risk of atherosclerosis. The aim of the study was to test the hypothesis that CMML patients are at increased risk of developing cardiovascular disease (CVD) due to persistent monocytosis and sustained chronic inflammation. In a retrospective cohort study, we assessed hazards for cardiovascular events after diagnosis in 112 CMML patients and 231 chronic lymphocytic leukemia (CLL) patients...
September 4, 2018: Annals of Hematology
David Cella, Jan McKendrick, Amber Kudlac, Antonio Palumbo, Abderrahim Oukessou, Ravi Vij, Teresa Zyczynski, Catherine Davis
Treatment of relapsed/refractory multiple myeloma (RRMM) aims to prolong survival while maintaining health-related quality of life (HRQoL) by managing disease-related symptoms and complications-one of the most frequent and debilitating being bone pain. In the ELOQUENT-2 study (NCT01239797), which evaluated the addition of elotuzumab to lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone, pain and HRQoL were assessed in patients with relapsed/refractory disease using the Brief Pain Inventory-Short Form (BPI-SF) and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 module (QLQ-C30) and myeloma-specific module (QLQ-MY20)...
September 4, 2018: Annals of Hematology
Ameet Patel, Mehmet H Kocoglu, Akash Kaul
No abstract text is available yet for this article.
September 3, 2018: Annals of Hematology
Sin-Syue Li, Ya-Ting Hsu, Chen Chang, Shang-Chi Lee, Chi-Chieh Yen, Chao-Neng Cheng, Jiann-Shiuh Chen, Sheng-Hsiang Lin, Kung-Chao Chang, Tsai-Yun Chen
Aplastic anemia (AA) is a rare disease characterized by pancytopenia and bone marrow failure. The incidence of AA tends to be higher in Asia than in the West, but real-world data about AA in Asia remain limited. We aimed to describe the basic data, treatment, and outcome of AA patients from our institute and evaluate the incidence of AA in Taiwan with a nationwide population-based cohort from National Health Insurance Research Database (NHIRD). We identified patients older than 2 years with AA in the Registry of Catastrophic Illness of NHIRD between 2001 and 2010 and excluded patients with any diagnosis suggestive of congenital or secondary bone marrow failure...
September 3, 2018: Annals of Hematology
Rie Tabata, Chiharu Tabata, Masahiko Okamura, Yusuke Takei, Koichi Ohshima
No abstract text is available yet for this article.
September 1, 2018: Annals of Hematology
Sandip Shah, Preetam Jain, Kamlesh Shah, Kinnari Patel, Sonia Parikh, Apurva Patel, Harsha Panchal, Asha Anand
Immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine A (CsA) is the first-line therapy for acquired aplastic anemia (AA) in those not suitable for bone marrow transplant. Horse ATG (hATG) is preferred for this purpose, but its use is often impeded by shortages and costs. Being a rare disease, there is limited data on this therapy. This study aimed to evaluate this therapy in a large cohort of AA patients from western India. We retrospectively analyzed AA patients who received an indigenous preparation of hATG along with CsA as first-line treatment, between 2012 and 2015, at our center and evaluated the response, survival, and occurrence of adverse events...
September 1, 2018: Annals of Hematology
M Faisal, G Büsche, J Schlue, H Kreipe, U Lehmann, S Bartels
No abstract text is available yet for this article.
August 29, 2018: Annals of Hematology
Zhao Xiaosu, Cao Leqing, Qin Yazhen, Wang Yu, Zhang Xiaohui, Xu Lanping, Huang Xiaojun, Chang Yingjun
Ninety acute myeloid leukemia (AML) patients with inv(16) were monitored CBFβ/MYH11 transcript around allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 23 patients received HLA-matched sibling donor transplantation (MSDT) and 67 patients received unmanipulated haploidentical hematopoietic stem cell transplantation (haplo-HSCT) were analyzed in this study. Patients were divided into four groups based on CBFβ/MYH11 expression prior to transplantation (pre-MRD): with negative (group 1)/positive (group 2) pre-MRD before MSDT; with negative (group 3)/positive (group 4) pre-MRD before haplo-HSCT...
August 29, 2018: Annals of Hematology
Kai Wille, Parvis Sadjadian, Tatjana Becker, Vera Kolatzki, Anette Horstmann, Christiane Fuchs, Martin Griesshammer
Venous thromboembolism (VTE) is a major burden in patients with BCR-ABL-negative myeloproliferative neoplasms (MPN). In addition to cytoreductive treatment anticoagulation is mandatory, but optimal duration of anticoagulation is a matter of debate. In our single center study, we retrospectively included 526 MPN patients. In total, 78 of 526 MPN patients (14.8%) had 99 MPN-associated VTE. Median age at first VTE was 52.5 years (range 23-81). During a study period of 3497 years, a VTE event rate of 1.7% per patient/year was detected...
August 28, 2018: Annals of Hematology
M Paz Garrastazul-Sánchez, Miriam Vilches-Moreno, M Carmen Fernández-Valle, Inmaculada Marchante-Cepillo, Concepción Prats-Martín, Ricardo Bernal, Rosario M Morales-Camacho
No abstract text is available yet for this article.
August 28, 2018: Annals of Hematology
Xiao-Ning Gao, Ji Lin, Shu-Hong Wang, Wen-Rong Huang, Fei Li, Hong-Hua Li, Jing Chen, Li-Jun Wang, Chun-Ji Gao, Li Yu, Dai-Hong Liu
Unmanipulated haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) has been an established treatment to cure high-risk leukemia/lymphoma. Relapse is the main cause of treatment failure for patients with relapsed/refractory disease or with very high-risk gene mutations such as TP53, TET2, and DNMT3a. In this study, we aimed to establish the tolerance and efficacy of prophylactic donor lymphocyte infusion (DLI) with G-CSF-primed peripheral blood progenitors for prevention of relapse in these very high-risk patients after haplo-PBSCT...
August 24, 2018: Annals of Hematology
Yoshiaki Abe, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Masami Takeuchi, Yoichi Kikuchi, Toshihiro Ouchi, Kengo Takeuchi, Kosei Matsue
To investigate the prevalence and clinical value of abnormal findings detected via brain magnetic resonance imaging (MRI) in patients with intravascular large B-cell lymphoma (IVLBCL), we identified 33 patients with IVLBCL pathologically diagnosed and evaluated with pretreatment brain MRI. Abnormal findings on brain MRI were categorized into four patterns: (1) hyperintense lesion in the pons on T2-weighted imaging (T2WI), (2) nonspecific white matter lesions, (3) infarct-like lesions, and (4) meningeal thickening and/or enhancement...
August 23, 2018: Annals of Hematology
Stephan Lobitz, Jeannette Klein, Annemarie Brose, Oliver Blankenstein, Claudia Frömmel
Sickle cell disease (SCD) is a severe inherited blood disorder associated with significant morbidity and mortality in early childhood. Since simple interventions are available to prevent early fatal courses, SCD is a target condition of several national newborn screening (NBS) programs worldwide, but not in Germany. Traditionally, the diagnosis of SCD is made by high-performance liquid chromatography (HPLC), isoelectric focusing (IEF), or capillary electrophoresis (CE), but globally, most NBS programs in place are based on tandem mass spectrometry (MS/MS)...
August 21, 2018: Annals of Hematology
Shaoxuan Hu, Daobin Zhou, Wei Zhang
The optimal timing and sequencing of radiotherapy (RT) and chemotherapy (CT) in the treatment of limited-stage extranodal NK/T cell lymphoma (LS-ENKTL) has not been elucidated. The aim of this meta-analysis was to evaluate whether the timing of RT in relation to CT affects the survival of patients with LS-ENKTL. We searched Medline, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, , and relevant meeting abstract databases from inception through April 2018 without age or language restrictions...
August 20, 2018: Annals of Hematology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"